Efficient allocation of novel agents in Multiple Myeloma: A work in progress by Gaultney, J.G. (Jennifer G.) & Uyl-de Groot, C.A. (Carin)
Payers of healthcareworldwide are concernedwith the rising
costs of healthcare. The costs of oncology care alone have in-
creased [1], with the size of the oncologymarket havingmore
than doubled since 1997, reaching $35 billion in 2006 [2]. Sci-
entific advances, particularly the development of targeted
agents, are a contributing factor to the rise in oncology costs.
Patient outcomes have improved, but at significantly higher
costs compared to conventional therapies. Over the past 40
years the median monthly costs of cancer drugs have risen
from less than $100 in 1965–1969 to more than $5000 in
2005–2009 (2007 prices) [3], with cancer drugs now account-





Together with improvements in stem cell transplantation and
supportive care [7, 8], theirusehasextended theexpectedover-
all survival from diagnosis [9]. However, the gains in health are
not distributed equally, with some patients’ health improving
more significantly thanothers [10].Given the substantial impact
of these novel agents on the healthcare budget, a better under-
standingof their relative cost-effectivenesswouldaid in their ef-
ficient allocation. The key questions in multiple myeloma,
addressed by two articles in this month’s issue [11, 12] include
howmuchdonovel agents cost?Whatare theirhealthbenefits?
Can their use bemore efficiently allocated? Using different ap-
proaches, both studies performed an economic evaluation to
cometo somewhat similar conclusions.
Teitelbaum et al. estimated the real-world costs of novel
agents based on patient-level claims data from a large U.S.
healthplan. This study is impressive in the largenumberof pa-
tients thatwere included,encompassinga totalof4,836 treat-
ment episodes in 2,642 patients. The one-year costs of novel
agent treatment episodeswereestimatedafter correcting for
differences in the patient population. The results were not
surprising as they confirm the significant budget impact of
novel agents from previous studies [13–16]. Interestingly,
they are the first to report that that the costs of bortezomib-
based episodes ($112,359)were similar to those of non-novel
agent-based regimens ($112,060), while thalidomide-based
($130,468) and lenalidomide-based regimens ($159,158)
were significantly higher. Previous studies outside the U.S.
found that thalidomide-based regimenswere less costly com-
pared to bortezomib and lenalidomide [13–15]. The reasons
for this discrepancy include differences across studies in unit
price for generic versus branded thalidomide, treatment dos-
ages and duration, and patient condition. The authors also re-
port similar frequency in ambulatory visits by novel agent in
first-line treatmentepisodes, suggestingnoperceivedbenefit
oforal therapy (i.e., thalidomideand lenalidomide)over intra-
venous administration (i.e., bortezomib) in terms of patient
visits in newly diagnosed patients since frequent patient as-
sessments are performed regardless of regimen. There was,
however, a reduction in the number of predicted ambulatory
visits during lenalidomide in the relapsed/refractory setting,
which was also found previously [14], and is likely due to less
frequent patient visits for treatment-related adverse events.
The authors also provide new insight into the economic bur-
den of care from the patient perspective. Patient out-of-
pocket costs were found to be significantly higher during
thalidomide and lenalidomide episodes and were attributed
to the coverage gap for outpatient drugs in Medicare Part D.
This is an important finding revealing inequity in patient cost
burden that could adversely impact access to care and health
outcomes formany patients.
This study, however, tells only part of the story as costs
were limited to one year instead of the entire treatment epi-
sode, andnohealth benefitswere accounted for, thus leading
to false conclusions about value formoney in the caseofmore
costly regimens thatofferbenefitspastoneyear. Thestrength
in largepatientnumbersmayalsobea limitationbecausehet-
erogeneity conceals differences in benefits within narrowly
defined prognostic groups.
To address the question of efficiency for these drugs, it is
necessary to consider their total costs and health benefits be-
yondone year, especially given differences inmodeof admin-
istration, treatment duration, and adverse event profile.
Garrison et al. fill a consistent yet important evidence gap [17,
18] by addressing this question for a more narrowly defined
group. They are the first to perform amodeling study to eval-
uate the cost-effectiveness of all three novel agents in combi-
nation with melphalan prednisone (MP) in newly diagnosed
transplant-ineligible patients. Using results from various ran-
domized controlled trials [19–22], the authors compared the
costs, life-years (LYs) and quality-adjusted life years (QALYs)
over a period of 20 years for MP plus bortezomib (VMP), tha-
lidomide (MPT) and lenalidomide with maintenance (MPR-R)
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in a decision model. The results show VMP to be more effec-
tive than MP (4.187 LYs/2.994QALYs versus 2.864LYs/
2.049QALYs) but more costly ($119,102 versus $63,294).
Compared to MPT, VMP was further found to be cost-saving
(-$23,350) and slightly more effective (0.047LYs/0.043
QALYs). Incremental costs (-$129,256) and effects (0.778LYs/
0.566QALYs) were even higher when compared to MPR-R
though increased costsweremainly attributable to additional
maintenance therapy. Based on these findings, adding bort-
ezomib to theMP regimenwas argued to bemore cost-effec-
tive than adding thalidomide or lenalidomide in transplant-
ineligible patients. A preference for VMP over MPT is in
contrast, however, to previous findings in the U.K [23]., but is
explained by the differences in modeling methods and unit
costs for thalidomide.
Then again, are the results of modeling studies robust?
Garrison et al. ’s model was based on a number of assump-
tions, potentially creatingbias. Cost estimateswerenotbased
on actual patient data but instead on assumptions regarding
resource use and unit costs and a budget impact model from
independent data. The effectiveness was calculated for VMP
andMP using patient-level trial data, whereas published trial
resultswere used forMPT andMPR-R. The analysis forMPR-R
was further weakened since the trial results were immature
(i.e., interim analysis). To obtain a more robust estimate of
cost-effectiveness for MPR-R, a future study could incorpo-
rate the results of a currently ongoing phase III trial (E1A06)
comparingMPT-T andMPR-R.
Readersmayalsoquestionthepossibilityofbias intheresults
favoring bortezomib given that both studieswere fundedby the
manufacturer. To their credit, the authors disclosed funding and
attempted to address a number of methodological weaknesses
alongwith providing transparent assumptions.We nonetheless
urgereaderstointerprettheresultsinlightofthemethodological
limitationsdiscussedabove.Moreover, readers shouldacknowl-
edge the need for additional public funding of pharmacoeco-
nomicandoutcomesresearchstudies.Thefundingpartyofthese
studies typically depends on the type of question asked, who is
asking it, andperhaps diseaseburden [24]. Amore collaborative
effort has the advantage of addressingmultiple objectives for a
broader set of treatment options or care processes instead of
simply providing evidence of superiority for treatment options
onlyrelevanttostakeholderswithafinancial interest[25]. Includ-




izedmethodological guidelines available [26] for thoseperform-
ing, reporting, andevaluatingpharmacoeconomic studies.
It should be noted that the treatment combinations as-
sessed in these studies may soon be irrelevant for certain
groups as the treatment paradigm shifts toward multiple
novel agent combinations. Combinations of bortezomib and
thalidomide [27,28]or lenalidomide [29,30]havebothshown
improved response rates,with the former also improvingpro-
gression-freesurvival.However,neithercombinationdemon-
strated superior overall survival. Because no trials have
compared these rather expensive combinations to similarly
effective and less toxic combinations, some argue that these
optionsmayonlybe relevant for high-riskpatientswhodonot
benefit fromcurrentoptions [31],whichpresents anopportu-
nity for future studies assessing the value of novel agents.
Toconclude,wherecan theuseof thesedrugsbeassumed
efficient? At the moment, upfront VMP could be cost-effec-
tive compared to MPT or MPR-R in transplant-ineligible pa-
tients from a U.S. healthcare payer perspective. This finding
requires confirmation with patient-level data, preferably
from daily practice, which will require active interdisciplinary
collaboration and the sharing of existing data [32]. The value
ofobservational data shouldbeemphasized for future studies
since costsweremuch higherwhenbased on real-world data,
demonstrating that studies relying on assumptions for costs
are susceptible to underestimation.
This question remains unanswered for newly diagnosed
transplant-eligible patients as well as for the relapsed/refrac-
tory setting since existing studies are either outdated [33] or
not generalizable to the U.S [34, 35]. Future research in this
area should move away from addressing efficiency-related
questions in heterogeneous groups and instead focus on sub-
groups with homogenous prognoses, particularly by incorpo-
rating prognostic risk markers [36], as well as treatment
sequence [37]. When drawing conclusions from current and
future economic studies regardless of indication, it is impor-
tant that readers keep in mind that efficiency in one setting
maynot transfer toanother,duenotonlydue todifferences in
study methodology but also, and perhaps more importantly,
to differences in patient care, prognosis, and policies impact-
ing access to care.
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